Security Reports
Aerie Pharmaceuticals

Aerie Pharmaceuticals

This is a preliminary report on Aerie Pharmaceuticals’s security posture. If you want in-depth, always up-to-date reports on Aerie Pharmaceuticals and millions of other companies, consider booking a demo with us. UpGuard is the new standard in third-party risk management and attack surface management. Our security ratings engine monitors billions of data points each day.

UpGuard Security Rating

/ 950
UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Aerie Pharmaceuticals has good security practices.
Aerie Pharmaceuticals
Last updated
Last updated
Last updated today

Security report for Aerie Pharmaceuticals

Aerie Pharmaceuticals Inc. (NASDAQ: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

Aerie Pharmaceuticals Data Breaches and Security News

Relevant news, breaches and security articles relating to Aerie Pharmaceuticals.
Coming soon.
No recent security news.

More security reports

Compare Aerie Pharmaceuticals's security performance with other companies.
Deliver icon

Sign up to our newsletter

Get the latest curated cybersecurity news, breaches, events and updates in your inbox every week.
Abstract shapeAbstract shape
Free instant security score

How secure is your organization?

Request a free cybersecurity report to discover key risks on your website, email, network, and brand.
  • Check icon
    Instant insights you can act on immediately
  • Check icon
    13 risk factors, including email security, SSL, DNS health, open ports and common vulnerabilities
Website Security scan resultsWebsite Security scan ratingAbstract shape

Book a free demo

Book a free, personalized onboarding call with one of our cybersecurity experts.